MiraDx products

Although it is completely logical that inherited, germ-line genetic differences, present in all cells, including those of the immune system, will predict response and toxicity to developing immune therapies, there has been little study of the genomic areas studied by MiraDx to find such biomarkers. MiraDx discovered a panel of such mutations that predict both response and toxicity to anti-PD1 and anti-PDL1 therapies currently on the market. We are working with potential partners to incorporate these findings into the newer agents to allow better patients selection to achieve improved response and less toxicity from these exciting new therapies. We are additionally working with partners to apply these mutations to all classes of developing immunotherapies.

Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment. In addition, some patients respond not only locally to radiation, but also have an immune response that can help them to fight their cancer. Miradx is at the forefront in this field, with a leading radiogenomics program, applying our class of microRNA binding site mutations to identify patients that respond differently to radiation. Our first publication on this problem found that patients with the KRAS-variant have a weak immune response to radiation, requiring the addition of cetuximab to help (Jama Oncology, 2016).